InvestorsHub Logo

RainyDayWriter

07/28/18 4:31 PM

#45582 RE: SAMNOTSAMUEL #45581

SNS, even combined efforts of C.Everett Koop, Sanjay Gupta, Dr. Ben Carson (and the like) could contribute anything worthwhile to any discussion of this company's fundamentals and product efficacy.
Such contributions would be meaningless, senseless, sorely wasted efforts unless accompanied by intervention via the SEC and the FBI.



.

.

Fisher Man

07/28/18 11:20 PM

#45591 RE: SAMNOTSAMUEL #45581

I have no position for ethical reasons, as an eye surgeon, but I have been dropping in on the board as I am concerned it will go under. The treatment of OM with melphalan using the delcath system is by far the best treatment out there for metastatic disease. There is only one other immune treatment that even comes close, and it is by study only. Once approved, the treatment can be used off label for any other tumor metastatic to the liver.

I hope it makes it, but am not optimistic......it is apparent that further dilution is in store for current shareholders because they do not have the money to get where they need to go for the FDA....but I'm just an outsider looking in